PubMed Health⌕ Search

Biomedical subjects

Michio Mineshima

Publications and source records attributed to Michio Mineshima.

5 recordsLinked to original sources
PubMed2004

New trends in HDF therapies: validity of internal filtration-enhanced hemodialysis.

Internal filtration-enhanced hemodialysis (IFEHD), defined as HD therapy using a dialyzer designed for enhanced internal filtration, seems to be more convenient in comparison with HDF therapies. In this paper, the validity of IFEHD was discussed during an analytical study and experimental studies. As a result, the maximum internal filtration flow rate (Q(IF)) value increased with a smaller inner diameter (D), a longer effective length (L(eff)), and a larger density ratio (DR) value of the hollow fibers. The validity of IFEHD was clarified by an analytical study and experimental studies. Development of a dialyzer with enhanced internal filtration, however, should take account of the patient's safety, and hemolysis and endotoxin invasion form the dialysate to the patient should be avoided.

Equipment Design↗
PubMed2002

Double filtration plasmapheresis in critical care.

Many kinds of technologies have been introduced and successfully developed for therapeutic apheresis. Furthermore, several kinds of these technologies have also been applied in critical care. Double filtration plasmapheresis (DFPP), however, is rarely applied in this field in comparison with other treatments such as continuous hemofiltration, continuous hemodiafiltration, single filtration plasmapheresis, and plasma adsorption therapies. In this paper, the characteristics of the DFPP treatments for critical care are summarized. During the DFPP treatments, the patient's blood volume (BV) often decreases with time due to albumin loss induced by inadequate albumin infusion in a supplementation fluid. We examined the change of BV by a continuous hematocrit monitor, Crit-Line, during an in vivo study for 9 patients. As a result, albumin loss fairly occurred in DFPP treatments. The decrease of patient BV was induced by an oncotic pressure drop due to albumin loss and often resulted in a blood pressure drop. This is a serious problem for DFPP in critical care. We should avoid inadequate albumin infusion if the patient is suffering from these adverse effects. In order to determine the optimal concentration C(S) and volume V(S) values of a supplemented albumin solution, we introduced a variable blood volume model for albumin transport in DFPP.

Blood Volume↗
PubMed2002

[Phosphate removal in hemodialysis therapy].

The control of plasma phosphate concentration in a dialysis patient is important to prevent some bone diseases. There are, however, few studies for phosphate kinetics in dialysis patients. Although molecular weight of phosphatic ion, mainly exists in the intravascular compartment, is relatively low, removal dynamics of phosphatic ion from the patient by the hemodialysis treatment is not simple. A tendency of relatively lower reduction rate of plasma phosphate concentration with higher clearance of the dialyzer, therefore, was often shown in a typical dialysis patient. Establishment of a detailed kinetic modeling involving phosphate generation and transport between intra and extra vascular compartments is required for the phosphate dynamics during the dialysis treatment.

English Abstract↗